NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 292 filers reported holding NOVOCURE LTD in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,360,137 | -58.0% | 84,219 | +8.0% | 0.01% | -64.1% |
| Q2 2023 | $3,234,884 | +84961.4% | 77,949 | +23.3% | 0.04% | -33.9% |
| Q1 2023 | $3,803 | +93.0% | 63,232 | +135.5% | 0.06% | +51.3% |
| Q4 2022 | $1,970 | -99.9% | 26,855 | -36.2% | 0.04% | -49.4% |
| Q2 2022 | $2,924,000 | +1003.4% | 42,073 | +1091.5% | 0.08% | +1825.0% |
| Q4 2021 | $265,000 | -77.4% | 3,531 | -33.4% | 0.00% | -81.8% |
| Q2 2021 | $1,175,000 | -56.1% | 5,298 | -65.8% | 0.02% | -71.1% |
| Q4 2020 | $2,677,000 | +29.8% | 15,472 | -55.5% | 0.08% | -25.5% |
| Q2 2020 | $2,063,000 | +766.8% | 34,795 | +886.0% | 0.10% | +385.7% |
| Q1 2020 | $238,000 | -70.1% | 3,529 | -62.7% | 0.02% | -41.7% |
| Q4 2019 | $797,000 | -58.1% | 9,453 | -68.6% | 0.04% | -33.3% |
| Q2 2019 | $1,903,000 | -18.5% | 30,096 | -37.9% | 0.05% | -44.3% |
| Q1 2019 | $2,335,000 | +1097.4% | 48,470 | +190.2% | 0.10% | +2325.0% |
| Q2 2016 | $195,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |